A study of lidocaine jelly for pain relief in women receiving gonadotropin-releasing hormone analog injection during breast cancer treatment

Phase 4

• Conditions: Cancer; Premenopausal women with hormone receptor-positive breast cancer

• Registration Number: ISRCTN99910605
• Lead Sponsor: Changhua Christian Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-09
• Last Update Posted: 13 February 2023
• Study Completion: 2023-07-21

Recruitment & Eligibility

• Status: Ongoing
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Premenopausal women with hormone receptor-positive breast cancer who had undergone breast cancer operations and were indicated for GnRHa injection

Exclusion Criteria

1. Unwilling to receive application of topical lidocaine jelly
2. Refuse questionnaire survey of pain and anxiety score

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain and anxiety measured using a visual analog scale (VAS) at baseline and the 1st to 8th cycles of GnRHa injections

Secondary Outcome Measures

Name	Time	Method
evels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol measured using a blood test before and after the GnRHa injection